This study uses a CRISPR screen to identify genes critical for macrophage-mediated killing of prostate cancer cells, revealing AR as an immunomodulator that promotes resistance to macrophage attack.

bioRxiv · Jun 6, 2023Cancer Biology

Paradoxical activation of oncogenic signaling as a cancer treatment strategy

M. H. Dias, A. Friskes, S. Wang, J. M. H. Fernandes Neto, F. v. Gemert, S. Mourragui, H. J. Kuiken, S. Mainardi, D. Alvarez-Villanueva, C. Lieftink, B. Morris, A. Dekker, E. v. Dijk, C. Papagianni, M. S. da Silva, , R. Bernards

This study shows that inhibiting PP2A and WEE1 together can kill colon cancer cells by causing DNA replication collapse and cell death, and that resistance to this treatment suppresses tumor growth.

bioRxiv · Feb 6, 2023Cancer Biology

Glucocorticoids regulate cancer cell dormancy

S. Prekovic, K. Schuurman, A. Gonzalez Manjon, M. Buijs, I. Mayayo Peralta, M. D. Wellenstein, S. Yavuz, A. Barrera, K. Monkhorst, A. Huber, B. Morris, C. Lieftink, J. Silva, B. Györffy, L. Hoekman, , W. Zwart

This study identifies the mechanism by which glucocorticoid receptor activation induces cancer cell dormancy through CDKN1C and FOXO1/IRS2 signaling, with implications for cancer therapy.

bioRxiv · Sep 4, 2019 · PreprintCancer Biology

phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer

R. R. Bernards, C. Wang, H. Jin, D. Gao, B. Evers, G. Jin, Z. Xue, L. Wang, R. Beijersbergen, W.-X. Qin

This study identifies phospho-ERK as a biomarker for response to sorafenib and MEK inhibition in liver cancer, showing synergistic effects in tumors with high phospho-ERK levels.

bioRxiv · Jan 23, 2018Cancer Biology